No Pharma Money
En Español
News & Reports
News November 20, 2026

The Week in Review in Prescription Drug Pricing: P4AD’s 7th Amicus Brief, Post-Election Community Polling, Senate Judiciary Hearing and more

By P4ADNow Team

P4AD CEO Highlights Patent Reform at Senate Judiciary Hearing

On Tuesday, P4AD CEO Merith Basey testified before the Senate Judiciary Committee, bringing the experience of patients directly to lawmakers and highlighting the real-world consequences of a drug price system rigged against them. Congress has an urgent opportunity to pass a slate of bipartisan drug price reforms as part of a year-end health package that would increase competition, lower drug prices, and save billions of dollars. Several of these bills have already advanced out of the Senate Judiciary Committee and would crack down on tactics drugmakers use to delay generic and biosimilar competition, including patent thickets, pay-for-delay deals, product hopping, and the abuse of FDA citizen petitions. Merith urged lawmakers to turn the bipartisan support behind these reforms into action and ensure patients see the benefits of greater competition. Watch Merith’s opening testimony, as well as her exchanges with Chairman Grassley (R-IA) and Senators Klobuchar (D-MN), Lee (R-UT), and Welch (D-VT). — [Sen. Judiciary, Epoch Times, IP Watchdog, 1819 News, Forbes, Financial Times, Bloomberg, ICIJ]

P4AD’s 7th Amicus Brief — Challenging AstraZeneca’s Second Lawsuit

P4AD filed its seventh patient-centered amicus brief defending the Medicare Negotiation Program, opposing AstraZeneca’s appeal of a lower court decision dismissing its challenge earlier this year. AstraZeneca is arguing that Medicare should treat the capsule and tablet versions of its cancer drug Calquence as entirely different medications — an interpretation that would allow drugmakers to use different formulations of the same drug to avoid or delay negotiation. This is AstraZeneca’s second attempt to use the courts to undermine Medicare negotiation after the Supreme Court declined to hear AstraZeneca’s first challenge in May. Despite repeatedly losing in court, the pharmaceutical industry continues to pursue new legal arguments to weaken the program. Courts have now ruled against the industry 25 times. Patients fought hard to secure Medicare negotiation, but their experiences are too often sidelined in legal challenges that will directly affect them. Our amicus brief brings those experiences directly into the courtroom, showing what is at stake for patients who stand to benefit from lower negotiated prices and why the program must be protected. — [P4AD Amicus Brief]

Post-Election Community Polling on Drug Pricing

In the week following the midterm election, we asked the P4AD community how high drug prices shaped their decisions at the ballot box. Among 1,166 respondents, 68% said both high drug prices motivated them to vote and that a candidate’s position on drug prices influenced who they voted for. Looking ahead, 88.7% of respondents said that it’s very or extremely important for Congress to take action to lower high drug costs. While this isn’t a representative poll of the electorate, the responses offer a snapshot of how patients and advocates engaged with the issue during the election — and what they expect from the new Congress. The results track with broader concerns about health care affordability: polling from POLITICO this week found that 36% of voters considered health care costs a major factor in their vote, second only to broader affordability concerns. — [POLITICO]

Stay Connected

Stay informed about the latest campaigns, policy developments, and ways to help lower prescription drug prices.